Effects of Vigabatrin on Evoked Potentials in Epileptic Patients
Overview
Affiliations
1. Somatosensory (SEP) brainstem auditory (BAEP) and visual (VEP) evoked potentials were determined before and after add-on administration of vigabatrin (GVG) in patients with epilepsy. 2. At pre-treatment assessment SEP and BAEP parameters were usually found to be within normal limits, while P100 latencies of the VEP were abnormally prolonged in a considerable proportion of patients. 3. In a double-blind, placebo-controlled trial in 22 patients GVG (1-3 g day-1 stratified according to body weight) given for 7 weeks did not modify any of the evoked potential parameters evaluated. 4. Eighteen patients were evaluated prospectively at regular intervals during long-term GVG (2-4 g day-1) therapy with a mean follow up of 24 months (range 13-42 months). SEP, BAEP and especially VEP parameters showed some interindividual variability, but the within patient variation was relatively small. No consistent important changes were seen in association with GVG, although a possible trend towards a shortening of BAEP latencies and P100 latencies was observed. 5. The relevance of these findings with respect to GVG safety is discussed.
Full-field ERG and visual fields in patients 5 years after discontinuing vigabatrin therapy.
Kjellstrom U, Lovestam-Adrian M, Andreasson S, Ponjavic V Doc Ophthalmol. 2008; 117(2):93-101.
PMID: 18188629 DOI: 10.1007/s10633-007-9108-3.
Examining visual field defects in the paediatric population exposed to vigabatrin.
Spencer E, Harding G Doc Ophthalmol. 2004; 107(3):281-7.
PMID: 14711160 DOI: 10.1023/b:doop.0000005337.39947.83.
Vigabatrin; its effect on the electrophysiology of vision.
Harding G, Robertson K, Spencer E, Holliday I Doc Ophthalmol. 2002; 104(2):213-29.
PMID: 11999628 DOI: 10.1023/a:1014643528474.
Multifocal ERG and full-field ERG in patients on long-term vigabatrin medication.
Ponjavic V, Andreasson S Doc Ophthalmol. 2001; 102(1):63-72.
PMID: 11475366 DOI: 10.1023/a:1017589301855.
A risk-benefit assessment of vigabatrin in the treatment of neurological disorders.
Srinivasan J, Richens A Drug Saf. 1994; 10(5):395-405.
PMID: 8037889 DOI: 10.2165/00002018-199410050-00004.